Skip to main content
PMC home page
BioMed Research International logoLink to BioMed Research International
. 2014 Jun 29;2014:729358. doi: 10.1155/2014/729358

Antimicrobial Effect of the Triterpene 3β,6β,16β-Trihydroxylup-20(29)-ene on Planktonic Cells and Biofilms from Gram Positive and Gram Negative Bacteria

Francisco Flávio Vasconcelos Evaristo 1, Maria Rose Jane R Albuquerque 2, Hélcio Silva dos Santos 2, Paulo Nogueira Bandeira 2, Fábio do Nascimento Ávila 2, Bruno Rocha da Silva 1, Ariana Azevedo Vasconcelos 1, Érica de Menezes Rabelo 1, Luiz Gonzaga Nascimento-Neto 1, Francisco Vassiliepe Sousa Arruda 1, Mayron Alves Vasconcelos 1,3, Victor Alves Carneiro 1, Benildo Sousa Cavada 3, Edson Holanda Teixeira 1,*
PMCID: PMC4100443  PMID: 25093179

Abstract

This study evaluated the antimicrobial effect of 3β,6β,16β-trihydroxylup-20(29)-ene (CLF1), a triterpene isolated from Combretum leprosum Mart., in inhibiting the planktonic growth and biofilms of Gram positive bacteria Streptococcus mutans and S. mitis. The antimicrobial activity was assessed by determining the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). The antibiofilm potential was determined by quantifying total biomass and enumerating biofilm-entrapped viable bacteria. In addition, the acute toxicity of CLF1 on Artemia sp. nauplii was also determined. The results showed that CLF1 was able in inhibiting the growth of S. mutans and S. mitis with MIC and MBC of 7.8 μg/mL and 15.6 μg/mL, respectively. CLF1 was highly effective on biofilms of both bacteria. Only 7.8 μg/mL CLF1 was enough to inhibit by 97% and 90% biomass production of S. mutans and S. mitis, respectively. On the other hand, such effects were not evident on Gram negative Pseudomonas aeruginosa and Klebsiella oxytoca. The toxicity tests showed that the LC50 of CLF1 was 98.19 μg/mL. Therefore, CLF1 isolated from C. leprosum may constitute an important natural agent for the development of new therapies for caries and other infectious diseases caused by S. mutans and S. mitis.

1. Introduction

The resistance to available antimicrobials is currently a public health concern in the world. Several types of infectious diseases have become difficult to treat and expensive to cure mainly due to the low efficiency of antimicrobials for current bacteria [1, 2]. Moreover, the socioeconomic impact caused by infectious diseases is quite significant as shown by the high amount of financial resources spent on the clinical treatment of patients [3, 4]. Taking this into consideration, the ability of microorganisms to grow as biofilms and the increased rate of microbial resistance to conventional antibiotics contribute to the expanding epidemiology of infectious diseases [5].

Biofilms are complex microbial communities that establish themselves on a wide variety of surfaces and are generally associated with an extracellular matrix consisting of different polymers [6, 7]. Biofilms provide protection against the action of antibiotics and supplies a barrier to prevent or reduce the penetration of antimicrobial agents through the matrix [8]. The eradication of microorganisms that live as biofilms becomes extremely difficult or even impossible [9, 10]. Therefore, the search for new molecules able to inhibit biofilm formation, either by inhibiting microbial growth or by inhibiting their adhesion to a substrate, has intensified in recent years.

The shrub Combretum leprosum Mart. is popularly known in Brazil as “mufumbo” or “cipoaba” and is commonly found in the northeast. In folk medicine, it is widely used as an expectorant, antimicrobial, and antihemorrhagic agent [11].

Although scarce, research on the biological activities of C. leprosum points to similar actions to those observed in other species of the same genus. Nunes and coworkers [11] provided evidences about gastroprotective and antiulcerogenic roles of the ethanolic extract (EE) from the bark of C. leprosum, which were attributed to the increase in mucus production and inhibition of gastric acid secretion in rats.

In the present study, we evaluated the antimicrobial potential of the triterpene 3β,6β,16β-trihydroxylup20(29)-ene (CLF1) isolated from leaves of C. leprosum Mart. on the Gram positive bacteria Streptococcus mutans and S. mitis and on the Gram negative bacteria Pseudomonas aeruginosa and Klebsiella oxytoca.

2. Materials and Methods

2.1. Strains and Culture Conditions

The Gram positive strains Streptococcus mutans UA159 (ATCC 700610) and S. mitis (ATCC 903) and the Gram negative strains Pseudomonas aeruginosa (ATCC 10145) and Klebsiella oxytoca (ATCC 13182) were kindly provided by the Oswaldo Cruz Institute (FIOCRUZ, Rio de Janeiro, Brazil). The growth of all strains started from a stock culture maintained at −80°C in BHI broth (Brain Heart Infusion, Himedia, Mumbai, India) with 20% glycerol. Each microorganism was inoculated in 10 mL of fresh sterile BHI broth and incubated for 24 hours at 37°C with or without 10% CO2 for Gram positive and Gram negative, respectively. After the initial activation, the culture was renewed by transferring 100 μL of inoculum into 10 mL of new sterile BHI broth and grown under the same conditions as previously reported.

2.2. Plant Material

Fresh leaves of C. leprosum were collected in June 2009 in Salgado dos Machados district, located 15 km from the city of Sobral, Ceará, Brazil. The plant authentication was performed by Professor Elnatan Bezerra de Souza, a plant taxonomist from Acaraú Valley State University (Sobral, Brazil), and a voucher specimen (N° 4573) has been deposited at the herbarium Francisco José de Abreu Matos (Sobral, Brazil).

2.3. Sample Preparation

Fresh leaves (2.5 kg) of C. leprosum were powdered and extracted at room temperature with an EtOH/H2O solution (8 : 2 v/v). After 15 days, the resulting material was subjected to a simple filtration, followed by evaporation of the solvents under reduced pressure. An aliquot of the obtained solution was then lyophilized, resulting in a crude ethanol extract (EECL). The EECL was suspended in MeOH/H2O 3 : 1 and partitioned with CH2Cl2, EtOAc, and n-BuOH. The CH2Cl2 extract was evaporated under reduced pressure, yielding a residue (15.5 g) that was fractioned over a Si gel and eluted with hexane/EtOAc (8 : 2, 6 : 4, 2 : 8), EtOAc, and MeOH. The hexane/EtOAc (6 : 4) fraction (4.19 g) was chromatographed over a Si gel and eluted with hexane/EtOAc (in a gradient of 9.5 : 0.5 to 0.5 : 9.5), EtOAc, and MeOH, resulting in 130 fractions which, after thin layer chromatography (TLC), were combined into 10 fractions (F1–F10). The F7 fraction (528 mg, resulting from elution with hexane/AcOEt 6 : 4) was rechromatographed using the same solvent system to purify CLF1 (54 mg).

2.4. Structural Analysis by Infrared Spectroscopy and Nuclear Magnetic Resonance

IR spectra were recorded using a Perkin-Elmer 1000 spectrophotometer. 1H and 13C NMR were recorded on a Bruker Avance DPX-500 (500 MHz for 1H and 125 MHz for 13C); chemical shifts are given in ppm (δ C and δ H) relative to CDCl3 (7.27) and (77.23).

2.5. Sample Preparation for Antimicrobial and Toxicity Assays

CLF1 was first solubilized in 99.9% dimethyl sulfoxide (DMSO), and then the concentration was adjusted to 62.5 μg/mL in sterile distilled water to a final concentration of 8% DMSO and serially diluted to obtain concentrations ranging from 31.25 to 3.9 μg/mL. The ethanolic extract of C. leprosum (EECL) was equally evaluated regarding its antimicrobial potential. Briefly, EECL was first solubilized in 99.9% DMSO, and then the concentration was adjusted to 500 μg/mL in sterile distilled water to a final concentration of 5% DMSO and submitted to twofold serial dilutions to obtain concentrations ranging from 250 to 31.25 μg/mL. Chlorhexidine at 125 and 31.25 μg/mL and distilled water with 8% DMSO were used as positive and negative controls, respectively.

2.6. Antibacterial Activity

The antibacterial effects of CLF1 and EECL were evaluated through a microdilution test in 96-well “round-bottom” polystyrene plates. First, the wells were filled with 100 μL of the bacterial suspension at 2 × 107 CFU/mL. Then, 100 μL of CLF1 or EECL was added at different concentrations as previously described, obtaining a final volume of 200 μL per well. The plates were incubated for 24 hours at 37°C with or without 10% CO2 for Gram positive and Gram negative, respectively.

The minimum inhibitory concentration (MIC) for each microorganism was determined to be the lowest CLF1 or EECL concentration that showed a complete inhibition of visible bacterial growth. To determine the minimum bactericidal concentration (MBC), 10 μL from each well, in which no visible growth was detected, was inoculated in Petri dishes containing fresh BHI agar and incubated at 37°C for 24 hours. MBC was considered to be the lowest concentration of compounds able to completely inhibit microbial growth on the plates.

2.7. Antibiofilm Activity

2.7.1. Biomass Quantification

Sterile 96-well “flat-bottom” plates were prepared using a procedure similar to that used in the antimicrobial activity tests, with the same concentration of cells. All plates were incubated on a horizontal shaker (120 rpm/min) at 37°C for 24 hours for biofilm development in the presence of CLF1 or EECL. Then, the supernatant of each well was removed and biofilms washed three times with 200 μL/well sterile water to remove cells weakly adhered. The attached biofilm mass was quantified using crystal violet (CV) staining [12]. Briefly, the plates containing biofilms were air dried for 30 minutes, and 200 μL of 99% methanol was transferred to each well and incubated for 15 minutes to fix the adhered cells. Then, the methanol was removed followed by addition of 200 μL/well of 0.1% CV (Gram-staining set for microscopy; Merck) and the plates were incubated for 5 minutes. After the staining step, the washing process was repeated with sterile water, and the plates were left to dry at room temperature. In order to solubilize the dye bounded to the biomass, 200 μL of 33% (v/v) acetic acid (Merck) was added to each well and the plates were agitated for 15 minutes on a horizontal shaker. The CV solutions were transferred to a new 96-well plate and the optical density of the content was measured using a plate reader (BioTrak II-Amersham Biosciences) at 590 nm.

2.7.2. Biofilm Cell Enumeration

In order to determine the effect of CLF1 on the viability of biofilm-entrapped cells, biofilms' suspension was prepared according the same conditions as previously described. After 24 hours of incubation at 37°C, the supernatant was discarded and the plates were washed with sterile water to remove the weakly adhered cells. Then, 200 μL of sterile water was added to each well and the plates were subjected to ultrasonic bath for 15 minutes to remove the biofilm-entrapped cells. The volume corresponding to five wells of each condition was then collected and pooled in a sterile 1.5 mL tube. The suspensions were serially diluted, plated on BHI agar, and incubated at 37°C for 24 hours. The number of colony-forming units (CFU) was determined and expressed as CFU/mL.

2.8. Acute Toxicity on Artemia sp

2.8.1. Nauplii Harvesting

To obtain viable nauplii, 30 mg of cysts was weighed and hydrated for 1 hour in distilled water under constant aeration. After hydration, the cysts were treated with 50% sodium hypochlorite under constant agitation, until the color of the cysts changed from brown to orange. In addition to acting in the corium layer by facilitating the nauplii outbreak, sodium hypochlorite also promotes cleansing of the cysts. When the cysts reached the orange color, they were immediately washed with distilled water to remove the sodium hypochlorite. The cysts were then transferred to a conical bottom tube containing filtered seawater under constant aeration and after 48 hours, the nauplii were ready to use in toxicity tests [13].

2.8.2. Toxicity Test

CLF1 was solubilized in seawater plus DMSO 8% to obtain a stock solution of 125 μg/mL. All tests were performed using 5 different concentrations of CLF1 (125, 62.5, 31.25, 15.6, and 7.8 μg/mL). A group with seawater with 8% DMSO was used to verify whether DMSO was toxic to the nauplii. Seawater alone was used as the negative control. All tests were carried out in triplicate and repeated three times independently. The assay was performed in 24-well polystyrene plates with 10 nauplii per well and the mortality was determined after 24 and 48 hours by analysis of the number of nauplii devoid of motility. To determine the LC50, the data were calculated and analyzed using the TSK (Trimmed Spearman-Karber) statistical program. Up to 10% mortality was considered acceptable in the negative control [13].

2.9. Statistical Analysis

Statistical analysis was performed by GraphPad Prism version 3.00 for Microsoft Windows. The method used was one-way ANOVA with Bonferroni post hoc test. The data were recorded in triplicate from at least three separate experiments and graphs are presented as mean ± standard deviation. The data were considered significant when P < 0.001.

3. Results

3.1. Purification and Structural Analysis of CLF1

CLF1 was purified as a white solid. Its infrared spectrum (IR) showed a broadband that indicated the presence of hydroxyl groups (3463 cm−1), as well as absorptions at 1643 and 883 cm−1 corresponding to a 1,1-disubstituted double bond moiety. This moiety was confirmed by chemical shifts of 13C [δ C 150.1 (C-20) and 110 (C-29)] and 1H [δ H 4.75 (br s, H-29a) and δ H 4.64 (br s, H-29b) NMR. The presence of three hydroxyl groups were supported by a chemical shift at δ C 76.9, 69.0, and 79.3, which, in the HSQC spectrum, showed correlations with the hydrogens at δ 4.52 (br s; H-16), 3.58 (dd, J = 11.2 and 4.4; H-6), and 3.12 (t, J = 6.7; H-3, resp.). Comparison of the chemical shifts with the literature data [14] revealed that CLF1 is the triterpene of the lupane skeleton named 3β,6β,16β- trihydroxylup-20(29)-ene, which was previously isolated by Facundo and coworkers [15] (Figure 1).

Figure 1.

Figure 1

Open in a new tab

Structure of 3β,6β,16β-trihydroxylup-20(29)-ene extracted from Combretum leprosum.

3.2. MIC and MBC

Both EECL and CLF1 inhibited the growth of Streptococcus mutans and S. mitis. However, CLF1 presented lower MIC and MBC values when compared to EECL (Table 1). On the other hand, the same effect was not seen on Gram negative Pseudomonas aeruginosa and Klebsiella oxytoca (data not shown).

Table 1.

Values of MIC, MBC, and biomass inhibition of Streptococcus mutans and S. mitis treated with ethanolic extract (EECL) and 3β,6β,16β-trihydroxylup-20(29)-ene (CLF1) from Combretum leprosum.

Microorganism MIC (μg/mL) MBC (μg/mL) Biomass inhibition (%)
EECL CLF1 EECL CLF1 EECL CLF1
Streptococcus mutans 125 7.8 250 15.6 97.3 97
Streptococcus mitis 62.5 7.8 125 15.6 44 90
Open in a new tab

When compared to EECL, CLF1 inhibited the growth of Streptococcus mutans more than 16-fold (Table 1).

3.3. Antibiofilm Activity

Regarding antibiofilm activity, the results showed that CLF1 was effective only on biofilms of Gram positive strains. At a concentration of 7.8 μg/mL, CLF1 inhibited the biomass of S. mutans and S. mitis by 97% and 90%, respectively. For EECL at 125 μg/mL the inhibition was approximately 97.3% for S. mutans and 44% for S. mitis. According to these findings, the CLF1 efficiency at 7.8 μg/mL is quite similar to that of chlorhexidine at 31.25 μg/mL for both bacteria (Figure 2).

Figure 2.

Figure 2

Open in a new tab

Effects of CLF1 on (a) Streptococcus mutans and (b) S. mitis biofilm mass. Biofilms were grown for 24 hours in the presence of CLF1 at different concentrations. The negative control was performed with 8% DMSO and the positive control with chlorhexidine at 31.25 µg/mL, and both are diluted in ultrapure water. Error bars represent standard deviation and statistical P value (represented by ∗ or #) indicates concentrations that are significantly different from negative and positive controls, respectively. *P < 0.001; # P < 0.001.

In order to evaluate the effect of CLF1 on biofilm-entrapped cells, S. mutans and S. mitis biofilms were grown in the presence of CLF1 at concentrations ranging from 7.8 to 0.95 μg/mL. The results showed that CLF1 at 7.8 μg/mL significantly decreased the viability of bacterial cells (Figure 3).

Figure 3.

Figure 3

Open in a new tab

Effect of CLF1 on viability of biofilm-entrapped cells from (a) Streptococcus mutans and (b) S. mitis. Biofilms were grown for 24 hours in the presence of CLF1 at different concentrations. The negative control was performed with 8% DMSO and the positive control with chlorhexidine at 31.25 µg/mL, and both are diluted in ultrapure water. Error bars represent standard deviation and statistical P value (represented by ∗ or #) indicates concentrations that are significantly different from negative and positive controls, respectively. *P < 0.001; # p < 0.001.

3.4. Toxicity Analysis

Analysis of acute toxicity with Artemia nauplii was carried out using 5 different concentrations of CLF1. In order to determine the LC50, the number of nauplii deprived of motility was evaluated after 24 hours of coincubation. The results showed that CLF1 presented a LC50 of 98.19 μg/mL, which is significantly higher than the concentration that kills bacteria in antimicrobial assays.

4. Discussion

The search for new molecules with remarkable antimicrobial activities has become an important area of study. Moreover, natural products are a rich source for discovery of new antimicrobial agents [16]. According to Newman and Cragg [17], studies involving medicinal plants with antimicrobial activities have great potential mainly due to the necessity of plants to produce natural products that protect them against infections.

Pathogenic microorganisms that form biofilms are the focus of intense research due to their involvement in a large number of chronic infections and their role in the colonization of medical instruments, such as cardiovascular devices [18]. These findings indicate an increasing need for more effective antimicrobial agents with lower costs [19].

Studies about the phytochemical and biological characteristics of C. leprosum can be readily found in the literature. Among them, a study by Facundo and coworkers in 1993 established the structures of three triterpenoids belonging to the lupane series [3β,6β,16β-trihydroxylup-20(29)-ene], oleanane (arjunolic acid) and cycloartenol (mollic acid), and two flavonoids derived from the quercetin (3-O-methylquercetin and 3-O-α-L-rhamnopyranosylquercetin) [15].

Triterpenes belong to class of terpenoids, which are chemically characterized by the presence of six isoprene units with a total of 30 carbon atoms. Such molecules are responsible for different biological activities found in plant extracts and essential oils [20].

The bioactive metabolite 3β,6β,16β-trihydroxylup-20(29)-ene (CLF1) was isolated from the dichloromethane fraction of ethanolic extract of C. leprosum leaves (EECL). This compound appears as a white solid with an average yield of 0.02%. As previously reported by Facundo and coworkers [15], this molecule was first isolated from the hexane and ethanolic extracts of leaves and roots of C. leprosum and identified as a triterpene of the lupane class, with a double bond between carbons 20 and 29.

Recently, Horinouchi and colleagues [21] provided important evidences about the antiproliferative and anti-inflammatory role of the ethanolic extract of flowers from C. leprosum. According to the authors, the extract must be considered as a new potential tool for the treatment of several skin inflammatory diseases, since it reversed the skin inflammatory and hyperproliferative process in a very significant manner.

In the present work, the antimicrobial activity of CLF1 was assessed on Gram positive bacteria Streptococcus mutans and S. mitis. MIC and MBC values for both bacteria are 7.8 and 15.6 μg/mL, respectively. No effects were seen on the growth of Pseudomonas aeruginosa and Klebsiella oxytoca, both Gram negative bacteria. Such MIC value is lower than that found by a casbane diterpene isolated from barks of Croton nepetaefolius, which wasevaluated on oral streptococci, including S. mutans and S. mitis [22]. Furthermore, several triterpenes isolated from different species from the genus Miconia presented antibacterial activity against oral streptococci with MIC ranging from 30 to 200 μg/mL [23].

S. mutans is a Gram positive bacterium highly acidogenic and aciduric, and several clinical and laboratory studies point to the involvement of this species as the primary pathogen in human dental caries [24]. Moreover, according to Gross and coworkers [25], S. mutans was the most abundant species observed in samples from children with caries.

Some studies have shown that Gram positive bacteria are more susceptible to the action of plant extracts that contain flavonoids and triterpenes [26]. Regassa and Araya [27] tested different species of the genus Combretum and elucidated the antimicrobial potential of Combretum molle ethanolic extract against Staphylococcus aureus and S. agalactiae, both Gram positive bacteria.

The effect of CLF1 on biofilm development was similar to that found on planktonic growth. CLF1 at 7.8 μg/mL inhibited biofilms' mass by 97% and 90% for S. mutans and S. mitis, respectively, and reduced the number of biofilm-entrapped cells. The effect of CLF1 on the inhibition of biofilm formation is likely associated with a decrease in cellular viability since the concentrations inhibiting the growth of biofilms and planktonic cells are similar. Sá and coworkers [22] found a diterpene with inhibitory properties on Streptococcus mutans biofilm-entrapped cells. Such diterpene inhibited S. mutans biofilms in 94.28%. In addition, Raja and coworkers [28] showed that a pentacyclic triterpenoid (acetyl-11-keto-b-boswellic acid) inhibited the biofilm formation and reduced preformed biofilms from S. mutans and Actinomyces viscosus at concentrations ranging from 16 to 128 μg/mL. Nevertheless, other chemical structures based on terpenoids have been described in the literature as molecules possessing antimicrobial activities [29–32].

Studies from 1987 to 2004 involving secondary metabolites suggest that the antibacterial activity exerted by these compounds may be associated with mechanisms such as damage to the plasma membrane (perforation and/or reduction in membrane fluidity) [33], inhibition of nucleic acid synthesis (inhibition of topoisomerases), and inhibition of the energetic metabolism (caused by inhibition of reductase and NADH cytochrome-c) [34].

Katerere and coworkers [35] reported that some pentacyclic triterpenes isolated from Combretum and Terminalia genera proved to be ineffective against Gram negative bacteria. In such study, CLF1 showed no significant effects on the growth of Escherichia coli.

Thus, based on the mechanisms of action of the compounds cited above, and considering the results of our study, the antimicrobial activity of CLF1 may be related to its hydrophobicity. This feature probably allows a nonspecific interaction with cell membrane phospholipids of Gram positive bacteria. The presence of an outer membrane composed by phospholipids, lipoproteins, and, particularly, lipopolysaccharides (LPS) in Gram negative probably blocks the interaction of the molecule with the plasma membrane [36, 37].

Finally, a limiting factor in the prospection of new molecules with antimicrobial potential is the toxicity exhibited by several compounds. In the present study, the LC50 of CLF1 on Artemia nauplii is higher than its MIC. Thus, the results are very promising and CLF1 must be considered as a new antimicrobial agent against infections by S. mutans and S. mitis, including their associated biofilms. On the other hand, CLF1 is not indicated for infections caused by Gram negative bacteria, since only a small interference was seen on P. aeruginosa growth.

Acknowledgments

The authors thank CNPq (National Council for Scientific and Technological Development), CAPES, and FUNCAP for financial support and the Acaraú Valley State University, Sobral, CE, Brazil, for experimental support. Edson Holanda Teixeria and Benildo Sousa Cavada are senior investigators of CNPq.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors' Contribution

All authors contributed and approved this paper.

References

  • 1.Grundmann H, Klugman KP, Walsh T, et al. A framework for global surveillance of antibiotic resistance. Drug Resistance Updates. 2011;14(2):79–87. doi: 10.1016/j.drup.2011.02.007. [DOI] [PubMed] [Google Scholar]
  • 2.Mokoka TA, McGaw LJ, Mdee LK, Bagla VP, Iwalewa EO, Eloff JN. Antimicrobial activity and cytotoxicity of triterpenes isolated from leaves of Maytenus undata (Celastraceae) BMC Complementary and Alternative Medicine. 2013;13, article 111 doi: 10.1186/1472-6882-13-111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Jones J, Gastellu-Etchegorry M, Stenz FK, et al. Epidemiology, surveillance and control of infectious diseases in the European overseas countries and territories, 2011. Eurosurveillance. 2011;16(29):1–11. [PubMed] [Google Scholar]
  • 4.Rosenthal VD, Lynch P, Jarvis WR, et al. Socioeconomic impact on device-associated infections in limited-resource neonatal intensive care units: findings of the INICC. Infection. 2011;39(5):439–450. doi: 10.1007/s15010-011-0136-2. [DOI] [PubMed] [Google Scholar]
  • 5.Batoni G, Maisetta G, Brancatisano FL, Esin S, Campa M. Use of antimicrobial peptides against microbial biofilms: Advantages and limits. Current Medicinal Chemistry. 2011;18(2):256–279. doi: 10.2174/092986711794088399. [DOI] [PubMed] [Google Scholar]
  • 6.Abee T, Kovács AT, Kuipers OP, van der Veen S. Biofilm formation and dispersal in Gram-positive bacteria. Current Opinion in Biotechnology. 2010;22(2):1–8. doi: 10.1016/j.copbio.2010.10.016. [DOI] [PubMed] [Google Scholar]
  • 7.Flemming H, Wingender J. The biofilm matrix. Nature Reviews Microbiology. 2010;8(9):623–633. doi: 10.1038/nrmicro2415. [DOI] [PubMed] [Google Scholar]
  • 8.Costerton W, Veeh R, Shirtliff M, Pasmore M, Post C, Ehrlich G. The application of biofilm science to the study and control of chronic bacterial infections. Journal of Clinical Investigation. 2003;112(10):1466–1477. doi: 10.1172/JCI20365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Alhede M, Bjarnsholt T, Jensen PØ, et al. Pseudomonas aeruginosa recognizes and responds aggressively to the presence of polymorphonuclear leukocytes. Microbiology. 2009;155(11):3500–3508. doi: 10.1099/mic.0.031443-0. [DOI] [PubMed] [Google Scholar]
  • 10.Van Gennip M, Christensen LD, Alhede M, et al. Inactivation of the rhlA gene in Pseudomonas aeruginosa prevents rhamnolipid production, disabling the protection against polymorphonuclear leukocytes. APMIS. 2009;117(7):537–546. doi: 10.1111/j.1600-0463.2009.02466.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Nunes PHM, Cavalcanti PMS, Galvão SMP, Martins MCC. Antiulcerogenic activity of Combretum leprosum . Pharmazie. 2009;64(1):58–62. [PubMed] [Google Scholar]
  • 12.O'Toole GA, Kolter R. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Molecular Microbiology. 1998;30(2):295–304. doi: 10.1046/j.1365-2958.1998.01062.x. [DOI] [PubMed] [Google Scholar]
  • 13.Lagarto Parra A, Silva Yhebra R, Guerra Sardiñas I, Iglesias Buela L. Comparative study of the assay of Artemia salina L. and the estimate of the medium lethal dose (LD50 value) in mice, to determine oral acute toxicity of plant extracts. Phytomedicine. 2001;8(5):395–400. doi: 10.1078/0944-7113-00044. [DOI] [PubMed] [Google Scholar]
  • 14.Mahato SB, Kundu AP. 13C NMR Spectra of pentacyclic triterpenoids—a compilation and some salient features. Phytochemistry. 1994;37(6):1517–1575. [Google Scholar]
  • 15.Facundo VA, Andrade CHS, Silveira ER, Braz-Filho R, Hufford CD. Triterpenes and flavonoids from Combretum leprosum. Phytochemistry. 1993;32(2):411–415. [Google Scholar]
  • 16.Li JW, Vederas JC. Drug discovery and natural products: end of an era or an endless frontier? Science. 2009;325(5937):161–165. doi: 10.1126/science.1168243. [DOI] [PubMed] [Google Scholar]
  • 17.Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. Journal of Natural Products. 2007;70(3):461–477. doi: 10.1021/np068054v. [DOI] [PubMed] [Google Scholar]
  • 18.Padera RF. Infection in ventricular assist devices: the role of biofilm. Cardiovascular Pathology. 2006;15(5):264–270. doi: 10.1016/j.carpath.2006.04.008. [DOI] [PubMed] [Google Scholar]
  • 19.Saito ST, Trentin DDS, MacEdo AJ, et al. Bioguided fractionation shows Cassia alata Extract to inhibit Staphylococcus epidermidis and Pseudomonas aeruginosa growth and biofilm formation. Evidence-based Complementary and Alternative Medicine. 2012;2012:13 pages. doi: 10.1155/2012/867103.867103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Hill RA, Connolly JD. Triterpenoids. Natural Product Reports. 2011;28(6):1087–1117. doi: 10.1039/c1np00012h. [DOI] [PubMed] [Google Scholar]
  • 21.Horinouchi CDDS, Mendes DAGB, Soley BDS, et al. Combretum leprosum Mart. (Combretaceae): potential as an antiproliferative and anti-inflammatory agent. Journal of Ethnopharmacology. 2013;145(1):311–319. doi: 10.1016/j.jep.2012.10.064. [DOI] [PubMed] [Google Scholar]
  • 22.Sá NC, Cavalcante TTA, Araújo AX, et al. Antimicrobial and antibiofilm action of casbane diterpene from Croton nepetaefolius against oral bacteria. Archives of Oral Biology. 2012;57(5):550–555. doi: 10.1016/j.archoralbio.2011.10.016. [DOI] [PubMed] [Google Scholar]
  • 23.Scalon Cunha LC, Andrade E Silva ML, Cardoso Furtado NAJ, et al. Antibacterial activity of triterpene acids and semi-synthetic derivatives against oral pathogens. Zeitschrift fur Naturforschung C: Journal of Biosciences. 2007;62(9-10):668–672. doi: 10.1515/znc-2007-9-1007. [DOI] [PubMed] [Google Scholar]
  • 24.Tanzer JM, Livingston J, Thompson AM. The microbiology of primary dental caries in humans. Journal of Dental Education. 2001;65(10):1028–1037. [PubMed] [Google Scholar]
  • 25.Gross EL, Beall CJ, Kutsch SR, Firestone ND, Leys EJ, Griffen AL. Beyond Streptococcus mutans: dental caries onset linked to multiple species by 16S rRNA community analysis. PLoS ONE. 2012;7(10) doi: 10.1371/journal.pone.0047722.e47722 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Ríos JL, Recio MC. Medicinal plants and antimicrobial activity. Journal of Ethnopharmacology. 2005;100(1-2):80–84. doi: 10.1016/j.jep.2005.04.025. [DOI] [PubMed] [Google Scholar]
  • 27.Regassa F, Araya M. In vitro antimicrobial activity of Combretum molle (Combretaceae) against Staphylococcus aureus and Streptococcus agalactiae isolated from crossbred dairy cows with clinical mastitis. Tropical Animal Health and Production. 2012;44(6):1169–1173. doi: 10.1007/s11250-011-0054-4. [DOI] [PubMed] [Google Scholar]
  • 28.Raja AF, Ali F, Khan IA, et al. Acetyl-11-keto-b-boswellic acid (AKBA); targeting oral cavity pathogens. BMC Research Notes. 2011;4, article 406 doi: 10.1186/1756-0500-4-406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Ren D, Zuo R, Barrios AFG, et al. Differential gene expression for investigation of Escherichia coli biofilm inhibition by plant extract ursolic acid. Applied and Environmental Microbiology. 2005;71(7):4022–4034. doi: 10.1128/AEM.71.7.4022-4034.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Hu J, Garo E, Goering MG, et al. Bacterial biofilm inhibitors from Diospyros dendo. Journal of Natural Products. 2006;69(1):118–120. doi: 10.1021/np049600s. [DOI] [PubMed] [Google Scholar]
  • 31.Carneiro VA, Santos HS, Arruda FVS, et al. Casbane diterpene as a promising natural antimicrobial agent against biofilm-associated infections. Molecules. 2011;16(1):190–201. doi: 10.3390/molecules16010190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Raja AF, Ali F, Khan IA, et al. Antistaphylococcal and biofilm inhibitory activities of acetyl-11-keto-β-boswellic acid from Boswellia serrata . BMC Microbiology. 2011;11, article 54 doi: 10.1186/1471-2180-11-54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Tsuchiya H, Iinuma M. Reduction of membrane fluidity by antibacterial sophoraflavanone G isolated from Sophora exigua. Phytomedicine. 2000;7(2):161–165. doi: 10.1016/S0944-7113(00)80089-6. [DOI] [PubMed] [Google Scholar]
  • 34.Bernard F, Sablé S, Cameron B, et al. Glycosylated flavones as selective inhibitors of topoisomerase IV. Antimicrobial Agents and Chemotherapy. 1997;41(5):992–998. doi: 10.1128/aac.41.5.992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Katerere DR, Gray AI, Nash RJ, Waigh RD. Antimicrobial activity of pentacyclic triterpenes isolated from African Combretaceae. Phytochemistry. 2003;63(1):81–88. doi: 10.1016/s0031-9422(02)00726-4. [DOI] [PubMed] [Google Scholar]
  • 36.Kolodziejek AM, Schnider DR, Rohde HN, et al. Outer membrane protein X (Ail) contributes to Yersinia pestis virulence in pneumonic plague and its activity is dependent on the lipopolysaccharide core length. Infection and Immunity. 2010;78(12):5233–5243. doi: 10.1128/IAI.00783-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Silipo A, Molinaro A. The diversity of the core oligosaccharide in lipopolysaccharides. Subcellular Biochemistry. 2010;53:69–99. doi: 10.1007/978-90-481-9078-2_4. [DOI] [PubMed] [Google Scholar]

Articles from BioMed Research International are provided here courtesy of Wiley

RESOURCES